{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T01:53:21Z","timestamp":1774922001159,"version":"3.50.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Bespoke therapies represent a promising tool to address a diverse range of genetic and acquired conditions, offering new hope where conventional treatments have fallen short. With the rapid rise of bespoke therapies, profound ethical and regulatory challenges emerge, making it crucial to establish a comprehensive framework that ensures these treatments reach clinical settings and meet patients\u2019 needs as quickly as possible while protecting all parties involved. Although current guidelines are continually evolving to address the range of ethical tensions raised by these therapies, several gaps remain. A significant unresolved question is determining where personalized interventions fall on the research-care continuum and understanding the institutional, regulatory, and ethical implications when custom therapies are classified as research, care, or a mix of both. To address these questions, we introduce a conceptual model alongside practical guidance for the development, administration, and evaluation of individualized therapies, using CRISPR\/Cas9-based interventions for Duchenne Muscular Dystrophy as a case study. We argue that the goals of an intervention should be as individualized as the bespoke product itself, tailored to the specifics of each case. Rather than attempting to pinpoint the exact location of an intervention on the continuum, which may be hard to operationalize and have limited utility, our approach focuses on the practical details of how such interventions are administered and the individual component parts of an intervention. It advocates for transparent discussions among all partners to anticipate and adjust various components\/parameters along the process of administering individualized interventions. Our paper highlights the most critical of these parameters in (1) the planning and development of individualized therapies in laboratory settings, (2) their regulatory oversight, and (3) evaluation. By discussing these stages and parameters in detail, we aim to provide guidance on how to navigate the ethical complexities inherent to individualized interventions and offer a preliminary framework for balancing the interplay between research objectives and patient care needs. Acknowledging that the scientific rigor and adequacy of any new model must be evaluated, we also identify the types of evidence that are required to validate that our model effectively meets individual and societal needs.<\/jats:p>","DOI":"10.3389\/fmed.2025.1493832","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:13:30Z","timestamp":1737702810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A conceptual model and practical guidance for the development, administration, and evaluation of individualized therapies"],"prefix":"10.3389","volume":"12","author":[{"given":"Lucie","family":"Perillat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McFadyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Furlong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"ref1","volume-title":"Approved cellular and gene therapy products","year":"2024"},{"key":"ref2","volume-title":"CASGEVY","year":""},{"key":"ref3","volume-title":"Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies","year":"2019"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1089\/hum.2023.157","article-title":"The lived experience of pediatric gene therapy: a scoping review","volume":"34","author":"Kimberly","year":"2023","journal-title":"Hum Gene Ther"},{"key":"ref5","volume-title":"Gene transfer and the ethics of first-in-human research: Lost in translation","author":"Kimmelman","year":"2010"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41434-020-0143-y","article-title":"Toward a new framework for the development of individualized therapies","volume":"28","author":"Marks","year":"2021","journal-title":"Gene Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-94-017-7200-6_11","article-title":"Research ethics and N-of-1 trials","volume-title":"The essential guide to N-of-1 trials in health","author":"Crowden","year":"2015"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/0141076817721131","article-title":"The history and development of N-of-1 trials","volume":"110","author":"Mirza","year":"2017","journal-title":"J R Soc Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","article-title":"Clinical research for rare disease: opportunities, challenges, and solutions","volume":"96","author":"Griggs","year":"2009","journal-title":"Mol Genet Metab"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/s41591-021-01519-y","article-title":"Individualized therapy trials: navigating patient care, research goals and ethics","volume":"27","author":"Kane","year":"2021","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.3390\/cancers13215428","article-title":"N-of-1 trials in pediatric oncology: from a population-based approach to personalized medicine\u2014a review","volume":"13","author":"Kyr","year":"2021","journal-title":"Cancers"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"102639","DOI":"10.1016\/j.msksp.2022.102639","article-title":"A systematic review of N-of-1 trials and single case experimental designs in physiotherapy for musculoskeletal conditions","volume":"62","author":"Nikles","year":"2022","journal-title":"Musculoskeletal Sci Prac"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0197-2456(90)90003-K","article-title":"N of 1 randomized trials for investigating new drugs","volume":"11","author":"Guyatt","year":"1990","journal-title":"Control Clin Trials"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/09602011.2013.824383","article-title":"Revision of a method quality rating scale for single-case experimental designs and n-of-1 trials: the 15-item risk of Bias in N-of-1 trials (RoBiNT) scale","volume":"23","author":"Tate","year":"2013","journal-title":"Neuropsychol Rehabil"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/09602010903040691","article-title":"Single-subject designs as a tool for evidence-based clinical practice: are they unrecognised and undervalued?","volume":"19","author":"Perdices","year":"2009","journal-title":"Neuropsychol Rehabil"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/15265161.2019.1602175","article-title":"Innovative practice, clinical research, and the ethical advancement of medicine","volume":"19","author":"Earl","year":"2019","journal-title":"Am J Bioeth"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41587-019-0081-7","article-title":"What compassionate use means for gene therapies","volume":"37","author":"Chapman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/2168479016628918","article-title":"Institutional review boards as arbiters of expanded access to unapproved drugs: time for a change?","volume":"50","author":"Redman","year":"2016","journal-title":"Ther Innov Regul Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1086\/288768","article-title":"Health as a theoretical concept","volume":"44","author":"Boorse","year":"1977","journal-title":"Philos Sci"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780190612139.001.0001","volume-title":"Philosophy of medicine","author":"Broadbent","year":"2019"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.7208\/chicago\/9780226595177.001.0001","volume-title":"Care & Cure: An introduction to philosophy of medicine","author":"Stegenga","year":"2018"},{"key":"ref22","first-page":"1","article-title":"Chapter 1- ethical principles and concepts in medicine","volume-title":"handbook of clinical neurology","author":"Taylor","year":"2013"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/oso\/9780195187120.003.0007","volume-title":"Clinical judgment and the problem of particularizing. How doctors think","author":"Montgomery","year":"2005"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.shpsa.2022.08.018","article-title":"Clinical recommendations: the role of mechanisms in the GRADE framework","volume":"96","author":"Perillat","year":"2022","journal-title":"Stud Hist Phil Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1332\/174426413X662581","article-title":"Knowing what we are talking about: why evidence doesn\u2019t always travel","volume":"9","author":"Cartwright","year":"2013","journal-title":"Evid Policy"},{"key":"ref26","volume-title":"Principles of biomedical ethics","author":"Beauchamp","year":"2001"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1001\/jama.1992.03490170092032","article-title":"Evidence-based medicine: a new approach to teaching the practice of medicine","volume":"268","author":"Guyatt","year":"1992","journal-title":"JAMA J Am Med Assoc"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jclinepi.2016.03.026","article-title":"N-of-1 trials can be aggregated to generate group mean treatment effects: a systematic review and meta-analysis","volume":"76","author":"Punja","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.jclinepi.2013.04.006","article-title":"Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research","volume":"66","author":"Duan","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hast.433","article-title":"The structure of clinical translation: efficiency, information, and ethics","volume":"45","author":"Kimmelman","year":"2015","journal-title":"Hastings Cent Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-13-173","article-title":"A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries","volume":"13","author":"Kimmelman","year":"2012","journal-title":"Trials"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"jme-2023-109729","DOI":"10.1136\/jme-2023-109729","article-title":"Understanding individualised genetic interventions as research-treatment hybrids","volume":"22","author":"Johnston","year":"2024","journal-title":"J Med Ethics"},{"key":"ref33","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-62241-0","article-title":"Scope validity in medicine","volume-title":"A pragmatic approach to conceptualization of health and disease","author":"Schermer","year":"2024"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/09593989409036400","article-title":"The ethics of single-system (n=1) research","volume":"10","author":"Sim","year":"1994","journal-title":"Physiother Theory Pract"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/520609a","article-title":"Time for one-person trials","volume":"520","author":"Shork","year":"2015","journal-title":"Nature"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/pme.11.7","article-title":"The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?","volume":"8","author":"Lillie","year":"2011","journal-title":"Pers Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development Subcommittee of the American Academy of neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2022-162353","article-title":"Efficacy and safety of a single dose of exagamglogene autotemcel for severe sickle cell disease","volume":"140","author":"Frangoul","year":"2022","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.celrep.2015.01.016","article-title":"Deletions, inversions, duplications: engineering of structural variants using CRISPR\/Cas in mice","volume":"10","author":"Kraft","year":"2015","journal-title":"Cell Rep"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"14161","DOI":"10.1038\/s41598-019-50649-4","article-title":"Time origin and structural analysis of the induced CRISPR\/cas9 megabase-sized deletions and duplications involving the Cntn6 gene in mice","volume":"9","author":"Pristyazhnyuk","year":"2019","journal-title":"Sci Rep"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat Commun"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J Control Release"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1615\/CritRevImmunol.2014011600","article-title":"Differences in innate immune response between man and mouse","volume":"34","author":"Zschaler","year":"2014","journal-title":"Crit Rev Immunol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40290-022-00451-x","article-title":"Somatic gene therapy research in pediatric populations: ethical issues and guidance for operationalizing early phase trials","volume":"37","author":"Bateman-House","year":"2023","journal-title":"Pharm Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41436-021-01245-3","article-title":"Ethical challenges for a new generation of early-phase pediatric gene therapy trials","volume":"23","author":"Iyer","year":"2021","journal-title":"Genet Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-016-0444-9","article-title":"Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers","volume":"11","author":"Morel","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"ref52","volume-title":"IND applications for clinical investigations: Regulatory and administrative components","year":"2022"},{"key":"ref53","volume-title":"Nonclinical testing of individualized antisense oligonucleotide drug products for severely debilitating or life-threatening diseases guidance for sponsor-investigators","year":"2021"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/wnl.0000000000011597","article-title":"Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders","volume":"96","author":"M\u00fcller","year":"2021","journal-title":"Neurology"},{"key":"ref55","volume-title":"June 21, 2023 summary basis for regulatory action \u2013 ELEVIDYS","year":"2023"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4324\/9781003074984-23","article-title":"Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: \u201ctranslating\u201d the translational","volume-title":"The ethical challenges of emerging medical technologies","author":"McCormack","year":"2020"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/B978-0-12-816507-2.00005-0","article-title":"Medical data harmonization","volume-title":"Medical data sharing, harmonization and analytics","author":"Pezoulas","year":"2020"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"907S","DOI":"10.3945\/ajcn.115.110387","article-title":"Current practices and challenges in the standardization and harmonization of clinical laboratory tests","volume":"104","author":"Vesper","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"h1793","DOI":"10.1136\/bmj.h1793","article-title":"CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/bmj.m122","article-title":"SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist","volume":"368","author":"Porcino","year":"2020","journal-title":"BMJ"},{"key":"ref61","volume-title":"IND submissions for individualized antisense oligonucleotide drug products for severely debilitating or life-threatening diseases: Clinical recommendations guidance for sponsor-investigators","year":""},{"key":"ref62","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/cpt.3087","article-title":"Practical and statistical considerations for the long term follow-up of gene therapy trial participants","volume":"115","author":"Rohde","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1073110520935352","article-title":"Facilitating both evidence and access: improving FDA's accelerated approval and expanded access pathways","volume":"48","author":"Lynch","year":"2020","journal-title":"J Law Med Ethics"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"114614","DOI":"10.1016\/j.socscimed.2021.114614","article-title":"\u201cWe measure what we can measure\u201d: struggles in defining and evaluating institutional review board quality","volume":"292","author":"Lynch","year":"2022","journal-title":"Soc Sci Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged\u2265 4 to< 8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"ref66","volume-title":"Center director decisional memo - ELEVIDYS","year":""},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/mt.2009.223","article-title":"Accepting risk in clinical research: is the gene therapy field becoming too risk-averse?","volume":"17","author":"Deakin","year":"2009","journal-title":"Molecular therapy"},{"key":"ref68","first-page":"1","article-title":"The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap","author":"Jonker","year":"2024","journal-title":"Nature Reviews Drug Discovery."},{"key":"ref69","first-page":"13.4.91","article-title":"Replicates and repeats\u2014what is the difference and is it significant? A brief discussion of statistics and experimental design","author":"Vaux","year":"2012","journal-title":"EMBO reports"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1748-720X.2000.tb00686.x","article-title":"The ethical analysis of risk","volume":"28","author":"Weijer","year":"2004","journal-title":"J. Law Med. Ethics."},{"key":"ref71","first-page":"e181","article-title":"Applying real-world data from expanded-access (\u201ccompassionate use\u201d) patients to drug development","volume":"7","author":"Wasser","year":"2003","journal-title":"J Clin Transl Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1493832\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T17:37:12Z","timestamp":1738777032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1493832\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":71,"alternative-id":["10.3389\/fmed.2025.1493832"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1493832","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"1493832"}}